You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明康德(603259.SH):擬認繳Sofinnova Capital X的2000萬歐元的A類份額
格隆匯 07-22 16:37

格隆匯7月22日丨藥明康德(603259.SH)公佈,2021722全資子企業WuXi PharmaTech Healthcare Fund I L.P. (WuXi Fund I)Sofinnova Partners (管理公司)簽署Subscription Agreement (認購協議),約定由WuXi Fund I認繳Sofinnova Capital X (投資基金)2000歐元的A份額A份額持有人佔已募集投資基金份額的9.7%(WuXi Fund I所持投資基金股份比例將隨投資基金後續從第三方投資機構募資而進一步稀釋)截至吿日,WuXi Fund I尚未支付投資款後續WuXi Fund I將以自資金根據投資基金章程的要求履行投資款的支付義務

投資基金一家依據法國法律成立的專業私募股權投資基金(Professional Private Equity Investment Fund),主要專注於在世界範圍內投資命科學領域(特別是生物醫藥及醫療器械行業)的中小型企業

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account